Amgen at PMWC 2027

Jan 27–29, 2027 Santa Clara, CA ~3k attendees Website

Amgen takes part in 3 sessions at PMWC 2027 in Santa Clara. Its program runs from targeted protein degradation and molecular glues to residual disease as a drug approval endpoint. It also joins a session on how payers decide what precision medicine gets covered.

OrganizationPMWC 2027 Attendance
Amgen
Thousand Oaks, CA
Large pharma
Biotechnology company with marketed medicines in oncology, inflammation, cardiovascular and bone disease, and a large research and development pipeline.
PMWC Pioneer Award honoree
Panel
Thu Jan 28
11:00am
Part of Track 4: Integration & Implementation of Precision Medicine
What Gets Covered and Why
with Rubrum Advising, EmblemHealth
Panel
Thu Jan 28
3:30pm
Part of Track 3: Liquid Biopsy – Therapy Guidance & Monitoring
MRD as a Surrogate Endpoint for Accelerated Drug Approval: Successes and Challenges
with University of Miami, Virginia Tech, Merck +4 more
Panel
Fri Jan 29
9:30am
Part of Track 1: Programmable Genetic Medicines
Programming Protein Fate: Molecular Glues, Degraders, and Induced Proximity
with Nurix Therapeutics, Stanford University

Explore the full PMWC 2027 dataset

Get in-depth attendee and institution profiles and research, to plan your meetings in Santa Clara. Leave your work email and we’ll be in touch.

Privacy

Download the full PMWC 2027 CSV

Leave your work email and we’ll be in touch. The CSV adds attendee names, roles and contact details to the company and session data shown here.

Privacy

Find decision makers at Amgen

Tell us what you sell and we’ll find the people at Amgen most likely to buy it.

  • Who to contact
  • Their contact info
  • What to say
  • Free, no sign-up

Not affiliated with or endorsed by PMWC or its organizers. Submit a correction